Telomeric G4s ligand 2

Telomeric G4s ligand 2 (CA11) binds selectively to dimeric telomeric G-quadruplex HTG57 with a K_d of 5.8 μM^[1].
Telomeric G4s ligand 2 (1 μM; 2 min equilibration after each addition) binds with high affinity to dimeric telomeric DNA and RNA G4s (K_d = 0.4 μM and 0.1 μM, respectively) and shows no measurable binding to monomeric G4s, non-G4 nucleic acids, or promoter G4s^[1].
Telomeric G4s ligand 2 (0-50 μM; 30 min at 37°C) inhibits the binding of G4-resolving helicases DHX36 and BLM to telomeric G4 DNA, with maximum inhibition rates of 80% and 50% at 50 μM, respectively^[1].
Telomeric G4s ligand 2 (0-25 μM) potently inhibits the unwinding of telomeric G4 DNA by its complementary antisense strand, reaching 90% inhibition at 25 μM^[1].
Telomeric G4s ligand 2 potently inhibits the proliferation of HCT116 colorectal cancer cells with an IC₅₀ of 0.4 μM^[1].
Telomeric G4s ligand 2 (0.25-0.5 μM; 48 h) dose-dependently induces telomere-specific DNA damage and dysfunction in both HCT116 and U2OS cancer cells, activates dual innate immune sensing pathways (TERRA-ZBP1 and cGAS-STING), induces autophagy^[1].
Telomeric G4s ligand 2 (0-100 nM; 9 days) potently inhibits long-term colony formation of U2OS, MC38, HCT116, and HeLa cancer cells

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.